Holly R. Steach

Holly R. Steach

Auto-generated profile, based on publicly available information

Holly R. Steach

Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Nature
Verified
Journal Article
Open access
PDF file
ESEsen Sefik
Esen Sefik
RQRihao Qu
Rihao Qu
CJCaroline Furtado Junqueira
Caroline Furtado Junqueira
EKEleanna Kaffe
Eleanna Kaffe
HMHaris Mirza
Haris Mirza
RFRichard A. Flavell
Richard A. Flavell
Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine production, viral RNA and a sustained interferon (IFN) response, all of which are recapitulated and required for pathology in the SARS-CoV-2-infected MISTRG6-hACE2 humanized mouse model of COVID-19, which has a human immune system1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20. Blocking either viral replication with remdesivir21,22,23 or the downstream IFN-stimulated cascade with anti-IFNAR2 antibodies in vivo in the chronic stages of disease attenuates the overactive immune inflammatory response, especially inflammatory macrophages. Here we show that SARS-CoV-2 infection and replication in lung-resident human macrophages is a critical driver of disease. In response to infection mediated by CD16 and ACE2 receptors, human macrophages activate inflammasomes, release interleukin 1 (IL-1) and IL-18, and undergo pyroptosis, thereby contributing to the hyperinflammatory state of the lungs. Inflammasome activation and the accompanying inflammatory response are necessary for lung inflammation, as inhibition of the NLRP3 inflammasome pathway reverses chronic lung pathology. Notably, this blockade of inflammasome activation leads to the release of infectious virus by the infected macrophages. Thus, inflammasomes oppose host infection by SARS-CoV-2 through the production of inflammatory cytokines and suicide by pyroptosis to prevent a productive viral cycle.

1 January 2016 in Immunity
Verified
Journal Article
Closed access
BHBrian D. Hondowicz
Brian D. Hondowicz
DADowon An
Dowon An
JSJason M. Schenkel
Jason M. Schenkel
KKKaren S. Kim
Karen S. Kim
HSHolly R. Steach
Holly R. Steach
MPMarion Pepper
Marion Pepper

3 February 2021 in Nature
Verified
Journal Article
Closed access
PDF file
PBPiotr Bielecki
Piotr Bielecki
SRSamantha J. Riesenfeld
Samantha J. Riesenfeld
JHJan-Christian Hütter
Jan-Christian Hütter
ETElena Torlai Triglia
Elena Torlai Triglia
MKMonika S. Kowalczyk
Monika S. Kowalczyk
RFRichard A. Flavell
Richard A. Flavell

13 February 2015 in Science
Verified
Journal Article
Closed access
PDF file
JTJustin J. Taylor
Justin J. Taylor
KPKathryn A. Pape
Kathryn A. Pape
HSHolly R. Steach
Holly R. Steach
MJMarc K. Jenkins
Marc K. Jenkins
For a single B cell, many roads to take: To successfully fight a pathogen, immunological B cells must wage a multipronged attack: They can differentiate into antibody-secreting plasma cells or become T cell–helping germinal center cells, or even long-lived memory cells. But can a single B cell acquire all of these different fates? To find out, Taylor et al. tracked the responses of single B cells in mice. Although some B cells acquired only one fate, others differentiated into all three. The authors linked the ability of B cells to differentiate into multiple subsets to their ability to proliferate and resist cell death, and the affinity of their antigen receptor. Science , this issue p. 784

8 April 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PCPing-Min Chen
Ping-Min Chen
PWParker C. Wilson
Parker C. Wilson
JSJustin A. Shyer
Justin A. Shyer
MVMargaret Veselits
Margaret Veselits
HSHolly R. Steach
Holly R. Steach
JCJoe Craft
Joe Craft
The kidney is a frequent target of autoimmune injury, including in systemic lupus erythematosus; however, how immune cells adapt to kidney’s unique environment and contribute to tissue damage is unknown. We found that renal tissue, which normally has low oxygen tension, becomes more hypoxic in lupus nephritis. In the injured mouse tissue, renal-infiltrating CD4+ and CD8+ T cells express hypoxia-inducible factor–1 (HIF-1), which alters their cellular metabolism and prevents their apoptosis in hypoxia. HIF-1–dependent gene-regulated pathways were also up-regulated in renal-infiltrating T cells in human lupus nephritis. Perturbation of these environmental adaptations by selective HIF-1 blockade inhibited infiltrating T cells and reversed tissue hypoxia and injury in murine models of lupus. The results suggest that targeting HIF-1 might be effective for treating renal injury in autoimmune diseases.

16 December 2022 in Science Immunology
Verified
Journal Article
Closed access
IOIan D. Odell
Ian D. Odell
HSHolly Steach
Holly Steach
SGStephen B. Gauld
Stephen B. Gauld
LRLauren Reinke-Breen
Lauren Reinke-Breen
JKJozsef Karman
Jozsef Karman
RFRichard A. Flavell
Richard A. Flavell
Immune cells are fundamental regulators of extracellular matrix (ECM) production by fibroblasts and have important roles in determining extent of fibrosis in response to inflammation. Although much is known about fibroblast signaling in fibrosis, the molecular signals between immune cells and fibroblasts that drive its persistence are poorly understood. We therefore analyzed skin and lung samples of patients with diffuse cutaneous systemic sclerosis, an autoimmune disease that causes debilitating fibrosis of the skin and internal organs. Here, we define a critical role of epiregulin-EGFR signaling between dendritic cells and fibroblasts to maintain elevated ECM production and accumulation in fibrotic tissue. We found that epiregulin expression marks an inducible state of DC3 dendritic cells triggered by type I interferon and that DC3-derived epiregulin activates EGFR on fibroblasts, driving a positive feedback loop through NOTCH signaling. In mouse models of skin and lung fibrosis, epiregulin was essential for persistence of fibrosis in both tissues, which could be abrogated by epiregulin genetic deficiency or a neutralizing antibody. Therapeutic administration of epiregulin antibody reversed fibrosis in patient skin and lung explants, identifying it as a previously unexplored biologic drug target. Our findings reveal epiregulin as a crucial immune signal that maintains skin and lung fibrosis in multiple diseases and represents a promising antifibrotic target.